Sprint Bioscience Competitors and Similar CompaniesClear all

Sprint Bioscience's competitors and similar companies include Chugai Pharmaceutical and Loxo Oncology.
Sprint Bioscience
Sprint Bioscience
Sprint Bioscience is a pharmaceutical company focused on developing drugs to fight cancer.
Chugai Pharmaceutical
Chugai Pharmaceutical
Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.
Loxo Oncology
Loxo Oncology
Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
Founding Date
Founding Date
2009
Founding Date
1925
Founding Date
2013
Type
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
Huddinge, SE HQ
Locations
Chuo City, JP HQ
Guangzhou Shi, CN
Taizhou, CN
Puteaux, FR
Frankfurt Am Main, DE
Singapore, SG
see more
Locations
Stamford, US HQ
Alcobendas, ES
Boulder, US
New York, US
South San Francisco, US
Employees
Employees
38
Employees
7,778
Employees
65610% decrease
Valuation ($)
Valuation ($)
13.8 m
Valuation ($)
78.7 b
Valuation ($)
N/A

Financial

Revenue (est.)
Revenue (est.)
kr167.2m (FY, 2025)
Revenue (est.)
¥1.3t (FY, 2025)
Revenue (est.)
N/A
Cost of goods
Cost of goods
kr13.1m (FY, 2025)
Cost of goods
¥363.7b (FY, 2025)
Cost of goods
N/A
Gross profit
Gross profit
kr154.3m (FY, 2025)
Gross profit
¥903.5b (FY, 2025)
Gross profit
N/A
Net income
Net income
kr91.7m (FY, 2025)
Net income
¥434b (FY, 2025)
Net income
($148.9m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 5.4m
Total funding raised
N/A
Total funding raised
$ 57m
For sources of this data, please see the company profile

View Company Profiles

Chugai Pharmaceutical
HQ
Chuo City, JP
Employees
7,778

Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases.

View company
Loxo Oncology
HQ
Stamford, US

Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.

View company